No Data
No Data
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $25
Oppenheimer analyst Francois Brisebois initiates coverage on $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a succes
Express News | Adverum Biotechnologies Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $25
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit
REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly
Express News | Adverum Biotechnologies Announces Appointments of DR. Rabia Gurses Ozden as Chief Medical Officer and DR. Szilárd Kiss as a Member of the Board of Directors
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation